Kentucky AG Secures 8-Year Sentence in Strangulation Case

Kentucky Attorney General Russell Coleman announced that the Special Prosecutions Unit helped secure an 8-year prison sentence for Hunter Diel, who pleaded guilty to strangulation and assault charges. The offender has a violent criminal past and was sentenced in McCracken County Circuit Court.

Kentucky AG Secures Indictment for Child Abuse Charges

The Kentucky Attorney General's Office announced the indictment of Aaron Alderman on charges of Criminal Abuse First Degree Child 12 or Under. The indictment alleges Alderman physically abused his infant son in June 2025, causing serious injuries.

SBA Disaster Declaration Amendment Correction for Washington

The Small Business Administration (SBA) issued a correction to a disaster declaration amendment for Washington State. This correction amends the incident period for the 2025 Severe Winter Storms disaster declaration. The physical loan application deadline remains April 27, 2026, and the EIDL loan application deadline is November 24, 2026.

FDA: Gluten Labeling and Cross-Contact Comment Period Extension

The Food and Drug Administration (FDA) has extended the public comment period for its request for information regarding gluten labeling and preventing cross-contact in packaged foods. The original notice was published on January 22, 2026, and the comment period is now extended to April 22, 2026.

FDA Guidance on Topical Drug Product Characterization for ANDAs

The FDA has issued a final guidance document for industry on the physicochemical and structural characterization of topical drug products submitted in abbreviated new drug applications (ANDAs). This guidance provides recommendations to assist applicants in identifying dosage forms and describing critical performance properties to support bioequivalence demonstrations for generic topical products.

OTC Monograph Drug Facility Fee Rates for FY 2026

The FDA has published the Over-the-Counter (OTC) Monograph Drug Facility (MDF) fee rates for fiscal year 2026. These fees are authorized by the Over-the-Counter Monograph Drug User Fee Amendments (OMUFA II) and support FDA's OTC monograph drug activities.

FDA Notice: Preparation for Cosmetics Regulation Meeting and Request for Comments

The FDA is requesting public comments to prepare for the twentieth International Cooperation on Cosmetics Regulation (ICCR-20) annual meeting. The input will help inform the agency's participation in discussions on cosmetics regulation. Comments are due by May 18, 2026.

FDA Determination: Methergine Injection Not Withdrawn for Safety or Effectiveness

The FDA has determined that Methergine (methylergonovine maleate) injection was not withdrawn from sale for safety or effectiveness reasons. This determination allows the FDA to approve abbreviated new drug applications (ANDAs) for generic versions of this product, provided other requirements are met.

FDA Advisory Committee Renewal: Obstetrics, Reproductive and Urologic Drugs

The Food and Drug Administration (FDA) has announced the renewal of the Obstetrics, Reproductive and Urologic Drugs Advisory Committee for an additional two years. The committee's charter will now be in effect until March 23, 2028, continuing its role in advising on drug safety and effectiveness.

USGS Earth MRI Competitive Cooperative Agreement Program Information Collection Notice

The U.S. Geological Survey (USGS) has published a notice regarding the renewal of an information collection for the Earth Mapping Resources Initiative (Earth MRI) Competitive Cooperative Agreement Program. The agency is requesting public comment on the necessity, accuracy, and utility of the proposed information collection.